In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins.
We compared the in vitro antibacterial activity of DU-6681a against Gram-positive and Gram-negative bacteria with that of R-95867, faropenem and oral cephalosporins such as cefcapene, cefotiam and cefpodoxime. DU-6681a is an active form of the new oral carbapenem compound DZ-2640, which is an ester-type prodrug, and R-95867 is an active form of the oral carbapenem CS-834. Against most Gram-positive bacteria, DU-6681a was as active as or two- to 16-fold more potent than R-95867 and faropenem in terms of MIC(90), and comparable to or two- to 64-fold more effective than the cephalosporins. Against most Gram-negative bacteria, the activity of DU-6681a was the same as or two- to 16-fold more potent than that of R-95867, and comparable to or two- to 2048-fold higher than that of faropenem and the cephalosporins.
Okuda
J
J
Department of Microbiology, Kyoto Pharmaceutical University, Yamashina-ku, Japan. okudao2e@daiichipharm.co.jp
Otsuki
M
M
Oh
T
T
Nishino
T
T
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D015780:Carbapenems / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D007769:Lactams; D008826:Microbial Sensitivity Tests; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D002511:Cephalosporins; C106854:DU 6681; C106855:DZ 2640; D007769:Lactams; C109885:R 95867; D047090:beta-Lactams; C107057:fropenem